Detail Article

Informations générales (source: ClinicalTrials.gov)

Numéro NCT

NCT04666961 En recrutement IDF

Titre

Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ (HORNEO01)

Type

Interventional

Pathologie

Carcinomes
Épithélioma in situ
Carcinome intracanalaire non infiltrant
Carcinome canalaire

Phase

Phase 2

Promoteur

Institut Cancerologie de l'Ouest (Voir sur ClinicalTrials)

Date de début

février 2021

Date de fin

août 2033

Dernière mise à jour

29 juin 2024

Résumé

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications. This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients. Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy. Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence. The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.

Détail

Voir le détail Description of the modalities for recruiting : Following screening and discovery of a DCIS, patients are referred to the center for surgical management. During a standard consultation, the surgeon presents the study to the patient who has been diagnosed with extensive DCIS with an indication for mastectomy. The surgeon provides the patient with the information note and the consent form to participate in the study. Once the consent form is signed by the patient and the investigator, the investigator prescribes a screening test to be performed within 30 days prior to the start of hormone therapy. Screening assessment includes : A clinical exam and a breast imaging exam (mammography and breast and axillary ultrasound). In case of a suspicious breast ultrasound image, microbiopsy will be performed to eliminate an infiltrating component. One or more macrobiopsy. Each biopsied site will be located using an X-ray clip inserted at the time of sample. A MRI post-macrobiopsy. Research of estrogen receptor expression Once the investigator has verified and validated all the eligibility criteria, the patient will be included. Prescriptions for Tamoxifen (non-menopausal patients) or Anastrozole (menopausal patients) are given to patients and dispensed by the center's pharmacy. Monitoring during treatment : Patients will benefit from imaging monitoring (Mammography, +/- breast ultrasound, +/- axillary ultrasound, MRI) at 3 months and 6 months during hormonotherapy. In case of progression observed during treatment, hormone therapy will be stopped and you will then benefit from a mastectomy. Surgery : Mastectomy or tumorectomy will be performed according to the tumor response to hormone therapy observed on MRI. All patients will benefit sentinel node detection. An additional axillary dissection will be performed based on the results of the sentinel node analysis. Analysis of biomarkers and tumor microenvironment before and after treatment on diagnostic macrobiopsies and on tumorectomy or mastectomy will be performed at Institut de Cancérologie de l'Ouest. Patients will be seen in postoperative consultation. Adjuvant treatments or re-surgical interventions will be prescribed, carried out, and the patients will be followed up and examined at 6 months after surgery or at the end of adjuvant treatments and then annually for 10 years (with control mammography). Patients who have had conservative surgery will have an MRI at 6 months from the end of radiotherapy. All patients will be asked to complete quality of life questionnaires at baseline, 6 and 12 months post-surgery, and annually for 9 years: EORTC QLQ-C30 (up to 5 years only), Short Form (36) Health Survey questionnaire. Fermer le détail

Etablissements

Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
CLCC INSTITUT CURIE	Enora LAAS, MD	Recrutement non commencé	Contact (sur clinicalTrials)
GH PARIS SITE SAINT JOSEPH	Séverine ALRAN, MD	En recrutement IDF	Contact (sur clinicalTrials)
Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données
Centre Antoine Lacassagne - 06189 - Nice - France	Marie GOSSET, MD	En recrutement	Contact (sur clinicalTrials)
ICO - Site Paul Papin - 49055 - Angers - France	Augustin P REYNARD, MD	En recrutement	Contact (sur clinicalTrials)
Institut Bergonie - 33076 - Bordeaux - France	Sophie AURIOL-LEIZAGOYEN, MD	En recrutement	Contact (sur clinicalTrials)
Institut de Cancérologie de l'Ouest - 44805 - Saint Herblain - France	Victoire BRILLAUD-MEFLAH, MD	En recrutement	Contact (sur clinicalTrials)
Institut de cancérologie de Montpellier - 34298 - Montpellier - France	Marian GUTOWSKI, MD	En recrutement	Contact (sur clinicalTrials)
IUCT-O - 31059 - Toulouse - France	Gabrielle SELMES, MD	En recrutement	Contact (sur clinicalTrials)

Critères

Genre

Femme

Nombre d'inclusion

Critère d'inclusion

Inclusion Criteria:

1. Patient ≥ 40 years old

2. Histological diagnosis of ductal carcinoma in situ without infiltrating contingent

3. Clinical T0N0

4. Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status

5. Indication for mastectomy

6. DCIS visible on MRI performed with clip sequence

7. Effective contraceptive method for women of childbearing age who are sexually active
and who have reported sexual activity.

8. Informing the patient and obtaining free, informed and written consent signed by the
patient and the investigator.

9. Affiliated patient or beneficiary of the social security system.

Critère de non inclusion

1. Invasive breast carcinoma

2. Lobular carcinoma in situ

3. pN+ patient

4. Indication for conservative surgery

5. Contraindications to anastrozole or tamoxifen

6. Concomitant treatments that may interact and reduce the efficacy of tamoxifen by
interaction with cytochrome CYP2D6.

7. Histologically proven multifocal lesion

8. Contraindication to breast MRI (pace maker, heart valve, metallic implant, neuronal
or peripheral stimulator, severe claustrophobia, ...)

9. History of homolateral breast cancer

10. Ongoing contralateral breast cancer

11. Known mutation BRCA1 BRCA2

12. Other cancer in progress at inclusion

13. Pregnant woman, or breastfeeding,

14. Persons deprived of liberty or under guardianship or trusteeship,

15. Impossibility to undergo the medical follow-up of the trial for geographical,
social, psychic or psychiatric reasons.

NCT04666961 - Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ (HORNEO01)

Informations générales
Etablissements
Critères
Accès à la fiche NCT

Retour en haut